CBX-12 is Cybrexa’s new lead development program

Cybrexa Therapeutics has announced CBX-12 (alphalexTM-exatecan) as its new lead development program. CBX-12 is an alphalexTM conjugate that includes the highly potent topoisomerase I inhibitor exatecan. CBX-12 has demonstrated strong efficacy and a solid safety profile in preclinical studies.

CBX-12 leverages the same class of payload used in the antibody-drug conjugate (ADC) ENHERTU® (fam-trastuzumab deruxtecan-nxki), which was recently approved by the U.S. Food and Drug Administration under Accelerated Approval in unresectable or metastatic HER2-positive breast cancer. more